In a 24‑year‑old female taking levothyroxine 75 µg daily with suppressed thyroid‑stimulating hormone (0.29 µIU/mL), low‑normal free triiodothyronine (2.5 pmol/L) and borderline high serum calcium (2.63 mmol/L), how should her levothyroxine dose be adjusted and what work‑up is indicated for the calcium level?

Levothyroxine Dose Management and Hypercalcemia Work-Up

Reduce the levothyroxine dose by 12.5 to 25 mcg (to 50-62.5 mcg daily) and recheck TSH in 6-8 weeks, while simultaneously investigating the elevated calcium with a PTH level to differentiate primary hyperparathyroidism from other causes.

Levothyroxine Dose Adjustment

The TSH of 0.29 mIU/L is suppressed below the normal reference range (typically 0.4-4.5 mIU/L), indicating subclinical hyperthyroidism from levothyroxine overtreatment. This is a critical finding in a 24-year-old woman because:

• Mortality risk increases when TSH falls outside the normal range in levothyroxine-treated patients 1
• Subclinical hyperthyroidism (TSH <0.1-0.45 mIU/L) increases risk of atrial fibrillation, cardiac dysfunction, and reduced bone mineral density 2
• The FDA label explicitly states to titrate levothyroxine by 12.5 to 25 mcg increments every 4-6 weeks until euthyroid 3

Dosing Algorithm:

1. Decrease levothyroxine by 12.5-25 mcg (from 75 mcg to 50-62.5 mcg daily)
2. Recheck TSH in 6-8 weeks 3
3. Target TSH: 0.5-2.5 mIU/L (lower half of normal range is acceptable for young adults without cardiac disease) 2
4. The low-normal T3 (2.5 pmol/L) suggests the patient may have a lower T3/T4 conversion ratio on levothyroxine monotherapy, but this does not justify maintaining a suppressed TSH 4

Critical Pitfall:

Do not maintain a suppressed TSH to "improve symptoms" or normalize the T3/T4 ratio—the increased cardiovascular and bone risks outweigh any theoretical benefit 2, 1.

Hypercalcemia Investigation

The calcium of 2.63 mmol/L (10.5 mg/dL, assuming upper limit of normal ~2.55 mmol/L) requires immediate work-up:

First-Line Test:

• Measure intact PTH level 5
  • If PTH is elevated or inappropriately normal → primary hyperparathyroidism
  • If PTH is suppressed → investigate malignancy, granulomatous disease, vitamin D toxicity, thiazide diuretics, or other non-PTH-mediated causes

Additional Initial Tests:

• Repeat ionized calcium (to confirm true hypercalcemia)
• 25-hydroxyvitamin D level
• Creatinine (assess renal function)
• Phosphate (typically low in primary hyperparathyroidism)

Important Consideration:

There is no direct mechanistic link between levothyroxine therapy and hypercalcemia, but chronic subclinical hyperthyroidism can accelerate bone turnover and potentially contribute to calcium elevation. Correcting the TSH may modestly improve calcium handling, but the hypercalcemia requires its own diagnostic pathway 2.

Monitoring Plan

1. Immediate: Order PTH, ionized calcium, vitamin D, creatinine, phosphate
2. 6-8 weeks: Recheck TSH and free T4 after dose reduction 3
3. Ongoing: Once TSH is normalized (0.5-4.5 mIU/L), monitor every 6-12 months 3

Drug Interaction Screening:

Verify the patient is not taking medications that interfere with levothyroxine absorption (calcium supplements, iron, proton pump inhibitors, estrogen) 6, 7. If she is taking calcium carbonate for the hypercalcemia, separate administration by at least 4 hours from levothyroxine 7.